At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
In Brief
A Phase 2 clinical trial evaluating Computed Tomography, Magnetic Resonance Imaging, and 4 other interventions for Hematopoietic and Lymphatic System Neoplasm and 37 related conditions. Active but no longer recruiting, targeting 1 participant across 174 sites in 3 countries.
Signals
Detailed Summary
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.
Study Details
Timeline
Arms & Interventions
Patients receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial.
Interventions
Undergo CT, PET/CT, and/or CT/MRI
Undergo MRI, PET/MRI, and/or CT/MRI
Undergo PET, PET/CT, and/or PET/MRI
Undergo scintigraphy
Given PO
Undergo x-ray imaging